BD Section 232 Tariff Relief Partnership with the Trump Administration
What happened
BD announced a partnership with the Trump administration under which it will invest $19 billion in U.S. manufacturing over several years, including $3 billion to expand strategic production sites and increase annual U.S. output by about 5 billion essential medical consumables, in exchange for relief from any future Section 232 tariffs on BD products, subject to undisclosed milestones. BD also agreed to make all of its needles used in the U.S. with American-made steel. The report does not state an effective date, a tariff rate, or the terms of the milestones.
Generated by AI from the reports · updated 17 days ago
Report timeline
Follow the reports to see the story from each side.
- Supply Chain DiveBD reaches supply chain pact with Trump administration for relief from future Section 232 tariffs
BD said it has struck a partnership with the Trump administration under which it will invest $19 billion in U.S. manufacturing over several years, including $3 billion to expand strategic production sites and increase annual U.S. output by about 5 billion essential medical consumables, in exchange for relief from any future Section 232 tariffs on BD products, subject to undisclosed milestones. BD also agreed to make all of its needles used in the U.S. with American-made steel. BD said it would not yet quantify the financial impact because final tariff rates and products were not determined, and it expects to provide more information when the Section 232 tariffs are finalized.